Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of S. cerevisiae to investigate repression of pleiotrophic drug resistance genes in using chimeric transcriptional repressors

ABSTRACT: Yeast is a powerful model system for studying the action of small molecule therapeutics. An important limitation has been low efficacy of many small molecules in yeast due to limited intracellular drug accumulation. We used the DNA binding domain of the pleiotropic drug resistance regulator Pdr1 fused in-frame to transcription repressors to repress Pdr1 regulated genes. Expression of these regulators conferred dominant enhancement of drug sensitivity and led to greatly diminished levels of Pdr1p regulated transcripts, including the yeast p-glycoprotein homologue Pdr5. Enhanced sensitivity was seen for a wide range of small molecules. Biochemical measurements demonstrated enhanced accumulation of rhodamine in yeast cells carrying the chimeras. These repressors of Pdr1p regulated transcripts can be introduced into large collections of strains such as the S. cerevisiae deletion set, and enhance the utility of yeast for studying drug action and for mechanism-based drug discovery. Experiment Overall Design: We determined the profiles of gene expression in yeast strains expressing dominant-negative Pdr1-fusion transcription factors. Yeast strains expressing different Pdr1-fusion repressors were analyzed by extracting total RNA and hybridization to Affymetrix GeneChip YG-s98 microarrays

ORGANISM(S): Saccharomyces cerevisiae

SUBMITTER: Geoffrey Neale

PROVIDER: E-GEOD-8326 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Repression of pleiotrophic drug resistance genes in Saccharomyces cerevisiae using chimeric transcriptional repressors

Project description:Yeast is a powerful model system for studying the action of small molecule therapeutics. An important limitation has been low efficacy of many small molecules in yeast due to limited intracellular drug accumulation. We used the DNA binding domain of the pleiotropic drug resistance regulator Pdr1 fused in-frame to transcription repressors to repress Pdr1 regulated genes. Expression of these regulators conferred dominant enhancement of drug sensitivity and led to greatly diminished levels of Pdr1p regulated transcripts, including the yeast p-glycoprotein homologue Pdr5. Enhanced sensitivity was seen for a wide range of small molecules. Biochemical measurements demonstrated enhanced accumulation of rhodamine in yeast cells carrying the chimeras. These repressors of Pdr1p regulated transcripts can be introduced into large collections of strains such as the S. cerevisiae deletion set, and enhance the utility of yeast for studying drug action and for mechanism-based drug discovery. Keywords: Comparison of genetic variants

2007-06-29 | GSE8326 | GEO

Effects of antimitotic drug benomyl on wild-type strain and strains with Yap1 or Pdr1 deletions

Project description:Time-course analyses of the modifications of the yeast gene expression program which immediately follows addition of the antimitotic drug benomyl. Parallel experiments were conducted in different genetic contexts using strains deleted in the Yap1 and Pdr1 genes. Keywords: other

2004-09-06 | GSE1617 | GEO

Effects of antimitotic drug benomyl on wild-type strain and strains with Yap1 or Pdr1 deletions

2004-09-06 | E-GEOD-1617 | biostudies-arrayexpress

Identification of genes regulated by Yox1 and Yhp1 in S. cerevisiae

Project description:We report gene expression data for yeast strains expressing mutated versions of the transcriptional repressors Yox1 and Yhp1 that can't be phosphorylated by Cdk1. For comparision, gene expression was also measured in cells with deletions in one or both repressors. Genes that are downregulatd in phosphomutant strains and upregulated in deletion strains are likely to be target genes of these transcriptional repressors.

2022-07-25 | GSE188177 | GEO

Inhibiting Fungal Multidrug Resistance by Disrupting an Activator-Mediator Interaction With the Small Molecule iKIX1

Project description:Eukaryotic transcription activators stimulate the expression of specific sets of target genes through recruitment of co-activators such as the RNA polymerase II-interacting Mediator complex. We previously identified an activator-targeted ~85 amino acid three-helix bundle KIX domain in the human MED15 Mediator subunit that is structurally conserved in Gal11 Mediator subunits in fungi. The Gal11 KIX domain is engaged by pleiotropic drug resistance transcription factor (Pdr1) orthologues, key regulators of the multidrug resistance (MDR) pathway in S. cerevisiae and in the clinically important human pathogen Candida glabrata. Drug-resistant clinical isolates of C. glabrata most commonly harbour point mutations in Pdr1 that render it constitutively active, suggesting that this transcriptional activation pathway may represent a lynchpin in C. glabrata MDR. We have now carried out sequential biochemical and in vivo high-throughput screens to identify small molecule inhibitors of the interaction of the C. glabrata Pdr1 activation domain with the C. glabrata Gal11A KIX domain. The lead compound (iKIX1) inhibits Pdr1-dependent gene activation in both S. cerevisiae and C. glabrata and re-sensitizes drug-resistant C. glabrata to effective azole antifungal concentrations in vitro and in animal models for disseminated and urinary tract C. glabrata infection.

2015-12-15 | GSE74361 | GEO

Inhibiting Fungal Multidrug Resistance by Disrupting an Activator-Mediator Interaction With the Small Molecule iKIX1

2015-12-15 | E-GEOD-74361 | biostudies-arrayexpress

Genomic targets sites of the Candida glabrata transcription factor Pdr1

Project description:Pdr1 is the major regulator of azole resistance in the fungal pathogen Candida glabrata. Earlier experiments demonstrated that expression of Pdr1 itself is increased when cells lose their mitochondrial genome (rho0). Here we use chromatin immunoprecipitation coupled with highthroughput sequencing (ChIP-seq) to map the genomic binding sites for Pdr1 in both normal and rho0 cells. These data provide the first look at genes that are likely to represent the direct targets of Pdr1 in this important pathogen. Examination of Pdr1 binding sites using two different antibodies in five different strains. Strains labeled TAP carry the TAP-tagged allele and capture was done with anti-TAP. The control was performed by carrying out a ChIP reaction on rho0 TAP-PDR1 cells but with no primary anti-TAP antibody. Since Pdr1 expression is the highest in this background, this was selected as the best control for antibody specificity. We also performed ChIP reactions on rho+, rho0 and cells lacking the PDR1 gene (pdr1D) cells using the anti-Pdr1 antibody. The control for these reactions was a ChIP experiment using anti-Pdr1 antibody on cells lacking the endogenous Pdr1 protein.

2014-09-12 | E-GEOD-59839 | biostudies-arrayexpress

Saccharomyces cerevisiae S288c

Project description:GNF179 Drug Selected Yeast Strains

| PRJNA376603 | ENA

Saccharomyces cerevisiae S288C

Project description:GNF179 Drug Selected Yeast Strains

| PRJNA381796 | ENA

Saccharomyces cerevisiae S288c

Project description:MMV001239 Drug Selected Yeast Strains

| PRJNA320899 | ENA